Merck Manual

Please confirm that you are a health care professional

honeypot link

Biosimilars Could Cut Spending for Biologic Therapy in the U.S.

01/21/22 By
HealthDay News
Biosimilars Could Cut Spending for Biologic Therapy in the U.S.

FRIDAY, Jan. 21, 2022 (HealthDay News) -- Biosimilar drugs could drive down prices for biologic drugs and generate savings of about $38.4 billion between 2021 and 2025, according to a study published online Jan. 3 in the American Journal of Managed Care.

Andrew Mulcahy, Ph.D., from RAND Corporation in Arlington, Virginia, and colleagues projected U.S. spending on biologics during a five-year period under three scenarios: (1) a baseline scenario holding quarter 4 (Q4) of 2020 market conditions constant; (2) under main assumptions allowing for biosimilar market growth and entry; and (3) an upper-bound scenario assuming greater biosimilar uptake, more robust price competition, and quicker biosimilar entry.

The researchers found that estimated biosimilar savings from 2021 to 2025 under their main approach were $38.4 billion, or 5.9 percent of projected spending on biologics during the same period. An estimated $26.1 billion of savings was accounted for by biologics first facing biosimilar competition from 2021 to 2025, with $12.2 billion from evolving market conditions for already-marketed biosimilars. Under the main approach, $24.6 billion of savings were from downward pressure on reference biologic prices rather than lower biosimilar prices. Under the upper-bound scenario, savings were substantially higher ($124.5 billion).

"Biosimilars have the potential to lower spending on biologic drugs that account for a rapidly increasing share of overall U.S. prescription drug spending," Mulcahy said in a statement.

Abstract/Full Text

Test your knowledge
Chest Imaging
Of the various imaging studies that can be done to assess for pulmonary disorders, only magnetic resonance imaging (MRI) is an absolute contraindication in patients who have which of the following characteristics?